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Abstract
The ubiquitous Epstein–Barr virus (EBV) is related to the development of several lymphoid and epithelial malignancies and is also the
aetiological agent for infectious mononucleosis (IM). BZLF1, an immediate early gene, plays a key role in modulating the switch from latency
to lytic replication, hence enabling viral propagation. Polymorphic variations in the coded protein have been studied in other geographical
regions in a search for viral factors that are inherent to malignancies and differ from those present in benign infections. In the present study,
in samples of paediatric patients with benign IM and paediatric patients with malignant lymphomas, we detected previously described
sequence variations as well as distinctive sequence polymorphisms from our region. By means of phylogenetic reconstruction, we
characterized new phylogenetically distinct variants. Moreover, we described an association between speciﬁc variants and the studied
pathologies in our region, particularly variant BZLF1-A2 with lymphomas and BZLF1-C with IM. Additionally, length polymorphisms within
intron 1 were also assessed and compared between pathologies resulting in an association between 29-bp repeated units and lymphomas. In
conclusion, this is the ﬁrst report to characterize BZLF1 gene polymorphisms in paediatric patients from our geographical region and to
suggest the association of these polymorphisms with malignant lymphomas.
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Introduction
The Epstein–Barr virus (EBV) is a ubiquitous herpesvirus that
latently infects over 90% of the world’s population. In
developing regions, primary infection usually occurs during
early childhood and is not associated with severe clinical
symptoms, although mild cases of infectious mononucleosis
(IM) may occur. On the other hand, in developed regions,
where primary infection is usually delayed until adolescence or
early childhood, it can cause a more severe case of IM [1].
Epstein–Barr virus is transmitted among individuals through
saliva, and following primary infection, latent infection is
established in memory B cells. Although latency supposes no
risk for the immunocompetent individual, it is this type of
infection that is usually associated with neoplastic pathologies
[2]; but the involvement of EBV in the aetiology, progression
and/or outcome of these malignancies is not yet fully under-
stood. Association of EBV with these pathologies varies
dramatically in different geographic regions (extensively
reviewed in [3]). Even though differences in viral association
may be accounted for by other factors, there has long been
interest in the possibility that disease-speciﬁc genetic variation
in EBV in different parts of the world might account for them [4].
Based on polymorphisms in nuclear antigens EBNA3A,
-3B and -3C, two different EBV types, EBV1 and EBV2, can
be distinguished. Given that these polymorphisms are not
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enough to describe the entire EBV natural variation, variants
and subvariants have been described based on polymor-
phisms in other viral antigens, such as BZLF1, EBNA1 and
LMP1 [3,4].
Particularly, the BZLF1 gene encodes for an immediate
early protein termed Zta, also called ZEBRA or EB1,
which is a master regulator for the expression of several
early viral genes that are critical for productive replication
of EBV. In this way Zta is responsible for the switch
between latent and lytic infection because it can initiate
the entire lytic cascade [5]. One of the earliest and most
critical functions of Zta is to activate its own expression
(acting in cis over its own promoter) and the expression
of Rta, the product of the BRLF1 gene [6,7]. Zta also
mediates viral DNA replication by speciﬁc binding to the
origin of lytic cycle replication (oriLyt) and recruiting viral
proteins [8].
The BZLF1 gene, which consists of three exons and two
introns with variable tandem repeats in the ﬁrst intron [3],
renders a 245 amino acid (aa) protein [8].
Though the functions of Zta are well established, there is
still very little information about naturally occurring polymor-
phisms present in different clinical samples from different
geographic regions [4]. To date, few studies have assessed Zta
polymorphisms, but mainly refer to EBV-associated gastric
carcinoma or nasopharyngeal carcinoma from Asia or Africa
[8–10].
As the incidence of EBV-associated malignancies differs
between geographical regions and EBV strains from different
regions or populations differ in their gene sequences, the
existence of tumour-speciﬁc variants is still a matter of debate.
Moreover, given the lack of information about natural variation
in the Zta protein from other geographical regions, deﬁnitive
conclusions regarding disease or geographical associations are
hampered.
In the present study, BZLF1 gene sequence variations from
our geographical region were characterized in peripheral
blood mononuclear cells (PBMCs) and oral secretions (OS)
from paediatric patients with IM as representative of a
replicative yet benign condition and in EBV+ lymphoma
biopsies as representative of latent infection in a malignant
condition.
Materials and Methods
Patients and samples
This study was conducted on 51 paediatric patients from
Argentina. Twenty-three children with IM, a median age of
4 years (range 1–17 years) and 52% male. Twenty-eight
patients had EBV-positive lymphomas (23 Hodgkin and 5
non-Hodgkin), median age 9 years (range 3–18 years) and 77%
male. Hospital ethics committees reviewed and approved this
study, which is in accordance with the human experimentation
guidelines of our institution. Written informed consent was
obtained from all patients’ parents.
Lymph node biopsy specimens were collected for lym-
phoma diagnosis before therapy. Presence of EBV was assessed
on formalin-ﬁxed, parafﬁn-embedded tissue sections by in situ
hybridization for EBV-encoded RNAs according to the
manufacturer’s instructions (Dako, Carpinteria, CA, USA).
Those patients who showed positive nuclear staining in
tumour cells without staining in inﬁltrating lymphocytes were
included.
Peripheral blood (6 mL) and OS samples were obtained
from patients with presumptive acute IM at the time of
diagnosis. Blood samples were obtained by venopuncture and
OS samples were obtained by pharyngeal swabbing. The IM
was identiﬁed on clinical grounds and conﬁrmed by indirect
immunoﬂuorescence assay, and those patients with IgM and
with or without IgG antibodies against virus capsid antigen
were included in the study.
DNA extraction
EDTA-PBMCs were separated from whole blood (6 mL) with
Ficoll-Paque plus (GE Healthcare, Little Chalfont, UK). Geno-
mic DNA was extracted from PBMCs, OS samples and lymph
node biopsy specimens using a QIAamp DNA minikit (Qiagen,
Hilden, Germany).
Epstein–Barr virus typing
The EBV type was determined based on polymorphisms in
EBNA3C gene as previously described [11].
Complete BZLF1 gene ampliﬁcation and sequencing
The BZLF1 gene was ampliﬁed by nested PCR of each sample.
Primers used in the ﬁrst round were 50-tcaaagagagccgacaggaag-
ata-30 (positions 102127–102150 of prototype EBV genome
strain B95.8, GenBank accession number V01555.2) and
50-cattgcaccttgccggccacc-30 (103175–103195). PCR was per-
formed in 25 lL using 200 ng of genomic DNA, 19 ampliﬁ-
cation buffer, 1 mM MgSO4, 0.2 mM dNTPs, 0.6 lM of each
primer, and 0.375 U Platinum pfx DNA polymerase, with
proof-reading activity (Invitrogen, Carlsbad, CA, USA). One
microlitre of this product was re-ampliﬁed with prim-
ers 50-aaacgaggcgtgaagcaggcgtgg-30 (102171–102194)
and 50-ccacctttgctatctttgctg-30 (103159–103179), yielding a
1008-bp fragment for B95.8 EBV. The reaction was performed
under the same conditions as those for the ﬁrst round. These
sets of primers suppose no selection of a particular BZLF1
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variant against any other because the targeted sequence is
conserved. P3HR1 cell line DNA was used as a positive
control and water was used as a non-template control. PCR
products were subjected to electrophoresis in 2% agarose gel
and puriﬁed with a QIAEXII gel extraction kit (Qiagen). These
puriﬁed PCR products were directly sequenced using a BigDye
Terminator 3.1 kit (Applied Biosystems, Foster City, CA, USA)
in an automated Genetic Analyzer 3130xl (Applied Biosys-
tems). At least two independent sequencing reactions (sense
and anti-sense) were performed with the inner primers to
conﬁrm each sequence.
Sequence analysis
The complete BZLF1 sequence was ampliﬁed and both intronic
sequences were then removed. Sequences were aligned,
translated and analysed with BIOEDIT v7.0.9.0 [12]. According
to the pattern of amino acid substitutions detected, Zta
sequence variants were classiﬁed according to the scheme
introduced by Luo et al. [8], because this scheme best ﬁtted
our data since it was the only one to consider the deletion of
aa 127, also found in our sequences. Brieﬂy, group A consists
of two variants (BZLF1-A1 and A2), which can be distinguished
based on speciﬁc signature amino acid substitutions compared
with prototype B95.8; Group B (B1, B2, B3, B4, B5) is deﬁned
by the deletion of codon 127 (alanine deletion) and other
signature amino acid substitutions. Finally, BZLF1-C variant is
conserved and equal to prototype B95.8 and also to the new
reference sequence for EBV genome (NC_007605.1). For
phylogenetic reconstruction, the most appropriate model of
evolution for this 245-aa protein was inferred and the
phylogenetic tree was calculated using maximum likelihood
under the previously deﬁned evolutionary model (Jones–
Taylor–Thomson model with discrete c distributions with ﬁve
rate categories, JTT + G for Fig. 1a and JTT for Fig. 1b,c) using
MEGA 5 [13]. Zta protein sequence from Macacine herpes-
virus 4 (RHV4, YP_067969.1), a related lymphocryptovirus
from monkeys, was used as an out-group. Bootstrap values
>70 were considered to merit as valid support for a tree
branch.
Multi-region gene phylogeny was also inferred (promoter
region variants and coding region variants) from previously
characterized variants in the promoter region of the BZLF1
gene [11]. To test statistically for benign versus malignant
association of these variants, the association index statistic,
parsimony score and monophyletic clade were computed using
a Bayesian tip-association signiﬁcance testing (BaTS) program
[14]. The BaTS program examines a posterior sample of trees
generated by a Bayesian Markov Chain Monte Carlo approach
implemented in BEAST v1.6.2 (Bayesian Evolutionary Analysis
Sampling Trees) [15].
Sequence accession numbers
All sequences have been deposited in GenBank under acces-
sion numbers KF826537–KF826610.
Statistical analysis
Statistical analysis was performed using GRAPH-PAD INSTAT
software, version 3.05 (Graphpad, La Jolla, CA, USA). Fisher’s
exact test was used to assess the association between
categorical variables. All tests were two sided, and p <0.05
was considered statistically signiﬁcant.
Results
DNA could be puriﬁed and ampliﬁed from all samples included
in the study.
EBV1 was the predominant viral type in both pathologies, in
22/23 patients with IM and 19/28 patients with lymphomas
(Tables 1 and 2). There were no differences in the viral type
detected in OS samples or PBMCs in patients with IM.
Unfortunately, due to the institution0s ethics committee
guidelines, PBMCs and OS samples were not available from
lymphoma patients.
Under the classiﬁcation scheme introduced by Luo et al. [8],
BZLF1-A2 variant was detected in one IM sample and ten
lymphoma samples. BZLF1-B4 variant was detected in two IM
samples and four tumour samples and BZLF1-C variant in 15
IM samples and ﬁve lymphoma samples (Tables 1 and 2).
Additionally, in every individual patient with IM, sequences
retrieved from PBMCs and OS from the same patient
possessed 100% identity between each other.
On the other hand, although with lesser frequency,
sequences with speciﬁc and not previously described muta-
tions were observed in more than one sample (Fig. 1). Hence,
sequences from samples IM15, T4 and T8 clustered separately
with a bootstrap support of 97 (Fig. 2a). Given that these
sequences differed signiﬁcantly from BZLF1-A, -B or -C
variants, they were characterized as a new phylogenetic group
termed BZLF1-D. This variant was characterized by several
substitutions, namely a tyrosine for an alanine at position 68
(T68A), S76P, Q105L, V129M, V141A, K161R and A206T
together with the absence of aa 127 deletion (Fig. 1).
Furthermore, this newly deﬁned variant was still found to
cluster independently from all other variants with no deletion
of aa 127 (Fig. 2b).
In a similar way, patients IM5, IM8, T13, T27 and T28, all
harboured substitutions L168V, A204S and the deletion of
aa 127, characteristic of BZLF1-B variants, but without a
signiﬁcant bootstrap support to exclude them from the
entire B group. As the bootstrap value for this cluster was
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87, they were characterized as a new BZLF1-B subgroup
termed BZLF1-B6 (Fig. 2a). When the phylogenetic recon-
struction was inferred taking only into account those
variants with the deletion of aa 127, BZLF1-B6 sequences
also segregated within the BZLF1-B group, but in an
independent manner (Fig. 2c).
Sequence variation in EBV proved to be even greater than
expected; variants with a mixed pattern of polymorphisms
were also detected. Even though sequences from patients
IM23, T3, T15 and T31 were very similar to BZLF1-B2 and
clustered in close relation in the original tree (Fig. 2a), none of
them contained the deletion of aa 127. Moreover, when these
sequences were tested against all other sequences without the
deletion (groups A and D), they clustered independently and
were therefore characterized as new BZLF1-E variants
(Fig. 2b). This new group harboured G111E, V129M and
V146A; however, they also displayed minor differences. While
samples from patients T3, T15 and T31 also contained a A205S
substitution, sample IM23 did not, but contained P57S and
A206S (Fig. 1).
FIG. 1. Schematic ﬁgure showing the complete Zta protein sequence alignment obtained from clinical samples and variant reference sequences. IM
indicates infectious mononucleosis samples and T indicates tumour samples. B95.8, Zta-A2, Zta-B2, Zta-B4 and Zta-C are the reference sequences.
Black, grey and white boxes delimit Zta antigen domains and brackets delimit the three coding exons in BZLF1 gene. Ruler shows amino acid
position. Only sequences with additional mutations to those described in the reference sequence are shown in the alignment.
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Finally, another set of samples, namely samples IM7 and T6,
presented a mixed substitution pattern containing all signature
substitutions of variant BZLF-A2 but also the deletion of aa
127 along with A135T and A204S substitutions (Fig. 1).
Sequences from these samples clustered together with A2
variants in the original tree, but segregated as an independent
group among all variants with deleted aa 127 (Fig. 2a,c).
Bootstrap of 100 supports the characterization of a new group
of BZLF1 variants, termed BZLF1-F, which also presented aa
127 deletion.
It is worth mentioning that samples from patients IM9, IM11
and IM20 and T5, T9, T23, T25, T26 and T30 contained
additional mutations to those originally described in the
reference variants. The most frequent were V129M, A135T,
K161R, L168V and A204S (Fig. 1). Even so, they did not merit
being characterized as new subvariants because no reproduc-
ible patterns of substitution were observed (Fig. 1). Moreover,
bootstrap values obtained after the phylogenetic reconstruc-
tion did not support, in any of these cases, their classiﬁcation
as different variants (Fig. 2a).
Regarding variant association with malignancy, variants
BZLF1-B4, -D, -E and -F were evenly distributed in both
pathologies (p >0.05 in all cases). On the other hand, while
BZLF1-C variant preferentially occurred in IM (p 0.0012),
BZLF1-A2 variant was statistically associated with its occur-
rence in lymphomas (p 0.0134). Given that some degree of
variation was observed within different samples with
BZLF1-A2 variant, and that certain substitutions are common
to other variants (e.g. V146A), tumour association for each
substitution detected in this series was assessed indepen-
dently. Curiously, only those substitutions described in the
original BZLF1-A2 variant showed a statistical association with
lymphomas and are shown in Table 3. Additionally, a multi-
region gene phylogenetic approach was used to assess the
association of variants in the coding region of Zta and
previously described variants in its promoter region [11] with
lymphomas. Interestingly, viral genomes containing the
BZLF1-A2 variant in the coding region and Zp-V3 variant in
the promoter region of Zta were statistically associated with
lymphomas (p 0.009).
Although not a coding region, length polymorphism within
the ﬁrst intron of BZLF1 gene was also described to be
associated with malignancy and/or compartmentalization [10];
so we also assessed this sequence variation in our IM and
lymphoma samples.
Length polymorphisms were detected both in the number
of repeated units and also in its length. Repeated units
consisted of 29 or 30 nucleotides that were repeated between
two and ten times (Tables 1 and 2). The most frequent
TABLE 1. Epstein–Barr virus (EBV) type and Zta variant
distribution in patients with infectious mononucleosis (IM)
Patient
code Sample
EBV
type
Polymorphisms in Zta
No repeats
in intron 1
aa 127
deletion Variant
IM1 PBMC/OS 1 2 rep 30 bp No BZLF1-C
IM2 PBMC/OS 1 2 rep 30 bp Yes BZLF1-B4
IM3 PBMC/OS 1 2 rep 30 bp No BZLF1-C
IM4 PBMC/OS 1 2 rep 30 bp No BZLF1-C
IM5 PBMC/OS 1 2 rep 30 bp Yes BZLF1-B6
IM6 PBMC/OS 1 2 rep 30 bp No BZLF1-C
IM7 PBMC/OS 2 3 rep 29 bp Yes BZLF1-F
IM8 PBMC/OS 1 2 rep 30 bp Yes BZLF1-B6
IM9 PBMC/OS 1 4 rep 29 bp No BZLF1-A2a
IM10 PBMC/OS 1 2 rep 30 bp No BZLF1-C
IM11 PBMC/OS 1 2 rep 30 bp No BZLF1-Ca
IM12 PBMC/OS 1 4 rep 30 bp No BZLF1-C
IM13 PBMC/OS 1 2 rep 30 bp No BZLF1-C
IM14 PBMC/OS 1 2 rep 30 bp No BZLF1-C
IM15 PBMC/OS 1 10 rep 30 bp No BZLF1-D
IM16 PBMC/OS 1 3 rep 30 bp Yes BZLF1-B4
IM17 PBMC/OS 1 2 rep 30 bp No BZLF1-C
IM18 PBMC/OS 1 2 rep 30 bp No BZLF1-C
IM19 PBMC/OS 1 2 rep 30 bp No BZLF1-C
IM20 PBMC/OS 1 2 rep 30 bp No BZLF1-Ca
IM21 PBMC/OS 1 3 rep 30 bp No BZLF1-C
IM22 PBMC/OS 1 2 rep 30 bp No BZLF1-C
IM23 PBMC/OS 1 3 rep 30 bp No BZLF1-E
Abbreviations: aa, amino acid; bp, base pairs; OS, oral secretions; PBMC,
peripheral blood mononuclear cells; rep, repeat.
GenBank Accession numbers to the sequences in the table are KF826537–
KF826582.
aVariants with additional substitutions with respect to the reference variant.
TABLE 2. Epstein–Barr virus (EBV) type and Zta variant
distribution in lymphoma patients
Patient
code
Lymphoma
type
EBV
Type
Polymorphisms in Zta
No repeats
in intron 1
aa 127
deletion Variant
T1 NHL 2 3 rep 29 bp No BZLF1-A2
T2 NHL 2 4 rep 29 bp No BZLF1-A2
T3 NHL 1 3 rep 30 bp No BZLF1-E
T4 HL 1 8 rep 30 bp No BZLF1-D
T5 HL 2 2 rep 29 bp No BZLF1-A2a
T6 HL 2 3 rep 29 bp Yes BZLF1-F
T7 HL 1 2 rep 30 bp No BZLF1-C
T8 HL 1 8 rep 30 bp No BZLF1-D
T9 HL 2 2 rep 29 bp No BZLF1-A2a
T10 HL 1 2 rep 30 bp Yes BZLF1-B4
T11 HL 1 2 rep 30 bp No BZLF1-C
T12 HL 1 2 rep 30 bp Yes BZLF1-B4
T13 HL 1 2 rep 30 bp Yes BZLF1-B6
T14 HL 1 2 rep 30 bp Yes BZLF1-B4
T15 NHL 1 3 rep 30 bp No BZLF1-E
T16 NHL 2 3 rep 29 bp No BZLF1-A2
T18 HL 1 2 rep 29 bp No BZLF1-A2
T19 HL 1 2 rep 30 bp No BZLF1-C
T23 HL 2 2 rep 29 bp No BZLF1-A2a
T24 HL 1 3 rep 29 bp No BZLF1-C
T25 HL 2 2 rep 29 bp No BZLF1-A2a
T26 HL 1 2 rep 30 bp No BZLF1-Ca
T27 HL 1 2 rep 30 bp Yes BZLF1-B6
T28 HL 1 2 rep 30 bp Yes BZLF1-B6
T29 HL 1 2 rep 30 bp Yes BZLF1-B4
T30 HL 1 4 rep 30 bp No BZLF1-A2a
T31 HL 1 3 rep 30 bp No BZLF1-E
T32 HL 2 3 rep 29 bp No BZLF1-A2a
Abbreviations: aa, amino acid; bp, base pairs; HL, Hodgkin lymphoma; NHL,
non-Hodgkin lymphoma; rep, repeat.
All samples are lymph node biopsies.
GenBank Accession numbers to the sequences in the table are KF826583–
KF826610.
aVariants with additional substitutions with respect to the reference variant.
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polymorphism in our series was two 30-bp unit repeats, in 16/
23 patients with IM and 11/28 patients with lymphomas. As
previously described, sequences from OS and PBMCs from IM
patients showed 100% identity. Interestingly, the 29-bp unit, no
matter the amount of repeats, preferentially occurred in
lymphomas and in BZLF1-A2 variants (p 0.022 and p 0.0001,
respectively).
Finally, an interesting ﬁnding was that the three sequences
characterized here as a new variant, BZLF1-D, all contained
high numbers of 30-bp unit repeats (Tables 1 and 2).
BZLF1-B6
BZLF1-D
BZLF1-A
BZLF1-B 
BZLF1-B 
and
BZLF1-C
BZLF1-B4 
and 
BZLF1-C
BZLF1-A2
BZLF1-E
BZLF1-B6
BZLF1-B4
BZLF1-D
BZLF1-A
BZLF1-F
(a) (b)
(c)
FIG. 2. Phylogenetic reconstruction. Trees obtained from the alignment of the complete protein sequence of the BZLF1 gene from patients with
infectious mononucleosis (IM) and Epstein–Barr virus (EBV) -associated lymphomas. Only oral secretions (OS) samples were included from IM
patients because both compartments harboured the same variant. Prototype sequences for each BZLF1 variant (Zta-A1, A2, B1 to B5 and Zta-C)
were characterized in ref. [8]. Bootstrap values obtained after 1000 resamplings are indicated. The scale bars represent a genetic distance calculated
by the number of base substitutions per site of 0.05. (a) Sequences from all patients were included in the original alignment. Variants BZLF1-B4 and
BZLF1-C appear as a single taxa in the tree because they only differ in the deletion of amino acid (aa) 127 and deleted positions are not compared by
phylogenetic software. (b) Tree obtained from the alignment of those sequences which did not contain the deletion of aa 127. (c) Tree obtained from
the alignment of those sequences which contained the deletion of aa 127.
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Discussion
Epstein–Barr virus sequence polymorphisms and their associ-
ation with a wide variety of tumours have been widely studied
in different geographical locations. Even though, deﬁnitive
conclusions regarding geographical and disease associations
are still lacking and particularly, information on EBV polymor-
phisms in South America is scarce. Moreover, much of the
existing literature focuses on EBV latency genes while it
disregards lytic genes and the notion that EBV reactivation
capability could be involved in lymphoma progression. To date
only a few studies have addressed sequence variation in the
coding sequence of BZLF1, an immediately early gene whose
product is responsible for the lytic phase switch (extensively
reviewed in refs [3,4]).
Based on phylogenetic analysis and following the terminol-
ogy introduced by Luo et al. [8], we characterized sequence
variation in the coding region of the BZLF1 gene in IM and
lymphoma patients from our geographic region as represen-
tatives of the lytic and latent EBV states, respectively.
In contrast to what was observed in Asia, where a
BZLF1-A1 variant (also called variant 5 in ref. [9]) was the
most prevalent in all types of samples analysed [8], in our
region BZLF1-C variant was the most frequently detected, but
still occurred preferentially in IM patients. Meanwhile, only 1/
89 samples presented this variant in Asia [8]. On the other
hand, variant BZLF1-A2, which was not associated with
nasopharyngeal or gastric carcinomas in Asia [8], was statis-
tically associated with lymphomas in our region. Moreover, the
presence of a 29-bp unit internal repeat, instead of a 30-bp unit
repeat, was also associated with lymphomas and in turn with
BZLF1-A2 variant. Hence, in our geographic region BZLF1-A2
variants with 29-bp repeated units could be among the factors
involved in lymphomagenesis.
With regards to length polymorphism, published data
provide conﬂicting results but most refer to the amount of
repeated units. While Ikeda et al. [16] described no differences
in compartmentalization of variants with two or three repeats
in a healthy population in Japan, in China Chen et al. [17]
reported that three 29-bp repeats were preferentially found in
tumours while two repeats were found in PBMCs. In contrast,
Sacaze et al. [10] reported three 30-bp units in PBMCs and
two 30-bp units in tumours in Tunisian patients with
nasopharyngeal carcinomas. In our study, no signiﬁcant differ-
ences were observed concerning the number of repeated units
between pathologies or in distribution between compartments
in IM patients. On the other hand, we reported a much greater
diversity in this aspect concerning both the number of
repeated units, ranging from two to ten repeats, as well as in
the length of each repeated unit, where both 29-bp and 30-bp
units were observed. Moreover, previously characterized
sequence variation in the promoter region of BZLF1 gene,
showed an association of Zp-V3 variant with tumours (M. A.
Lorenzetti, P. A. Chabay & M. V. Preciado, personal commu-
nication). This association was also described by other authors
regardless of the geographic location [18–21]. Moreover, the
association between the BZLF1-A2 and Zp-V3 variants with
lymphomas was also signiﬁcant by means of multi-region gene
phylogenetic analysis followed by BaTS. In addition, when
comparing all polymorphisms associated with malignancies,
variants characterized as Zp-V3 in the promoter region and
BZLF1-A2 in the coding region with 29-bp repeated units in
intron 1, occurred in nine lymphoma cases but only in one IM
case ([11] and M. A. Lorenzetti, P. A. Chabay & M. V. Preciado,
personal communication). Hence, this polymorphism combi-
nation appears to be associated with lymphomas in our region.
Our present results suggest not only the possible existence
of tumour-associated variants, but also the existence of
geographically distributed ones. The new BZLF1-D, -E and -F
variants appear to circulate preferentially in our region,
although deﬁnitive conclusions are precluded because reports
on this EBV genomic region are scarce and this is the ﬁrst
report to assess BZLF1 coding region polymorphisms from
South America. Furthermore, samples harbouring the newly
characterized BZLF1-D variant were the same as those that
were previously characterized as Zp-V3+51 variants in the
promoter region of the BZLF1 gene, another variant of
exclusive distribution in our region [11]. As previously
mentioned, given that only a few BZLF1 sequences are
available on GenBank, deeper phylogeographic studies are
not yet possible. However, the notion of geographical
distribution of EBV variants is not new and is mostly
exempliﬁed by EBNA1 gene, in which we previously charac-
terized a high proportion of V-leu variants, circulating in the
whole American continent, and V-ala variants, restricted to
South America [22].
TABLE 3. Lymphoma association for individual amino acid
substitutions
Substitution
Frequency
in lymphoma (%)
Frequency in
infectious
mononucleosis (%) p value
(T68A) 13/28 (46) 3/23 (13) 0.0152
(S76P) 13/28 (46) 3/23 (13) 0.0152
(T124P) 11/28 (39) 1/23 (4) 0.0063
(V146A) 16/28 (57) 4/23 (17) 0.0047
(V152A) 10/28 (36) 2/23 (7) 0.0441
(Q163L) 10/28 (36) 2/23 (7) 0.0441
(E176D) 10/28 (36) 1/23 (4) 0.0075
(Q195H) 10/28 (36) 2/23 (7) 0.0441
(A205S) 14/28 (50) 2/23 (7) 0.0021
Fisher0s Exact Test was applied in every case.
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No sequences, from either IM patients or lymphoma
patients, presented mutations in any of the speciﬁc amino
acids, namely N182, A185, S186, C189 and R190, within the
DNA-binding domain (aa 178–196), previously described as
essential for DNA binding and in turn, the activation of
downstream genes required for lytic switch [23,24]. Only
substitution Q195H was detected in BZLF1-A2 and BZLF1-F
variants but this was not assessed by Heston et al. [23].
Likewise, the present sequences had no mutations in the
N-terminal region of the protein, speciﬁcally in the BRLF1
cooperation domain (aa 25–42). With regards to the dimer-
ization domain (aa 197–221) in the C-terminal region, aa
substitutions were detected in positions 204, 205 and 206.
Previous work indicated that substitutions A205S and A206S
had no effect on Zta protein dimerization capability [25], but
there is no information about the possible effects of the
naturally occurring substitutions A204S and A206T. Further-
more, no mutations were detected in the conserved
coiled-coil dimerization region (aa 208–215) required for
EBV DNA replication [26].
Functional analysis of natural occurring variants, particularly
those with a high number of mutations within the trans-acti-
vation domain (aa 1–167), like BZLF1-A2 variant, are still
lacking and could provide a clear insight into the ability of the
virus to enter the lytic cycle and so help to conﬁrm if this
variant is associated with lymphoma development.
In a recent study, Yu et al. [27] demonstrated that a mutant
virus incapable of repressing BZLF1 transcription was unable
to establish latency and was consequently unable to transform
B cells in vitro, given that spontaneous reactivation caused
infected cells to die. However, this same mutant virus was able
to transform and induce B-cell lymphoma in an in vivo
humanized mouse model because most infected B cells appear
to have an abortive form of lytic gene expression that does not
result in the release of infectious virus particles or killing host
cells [28]. It could be speculated that a Zta protein with altered
capabilities in trans-activating lytic viral genes could produce a
similar phenotype, either by over-activating lytic genes, leading
to an abortive lytic cycle, or by failing to do so and preventing
transformed lymphoma cells from dying if they never undergo
spontaneous lytic reactivation. However, when viral load was
assessed in plasma (for IM cases) or tissue biopsy (for
lymphoma cases) in a proportion of the present cases, no
correlation was found between viral copy number and BZLF1
polymorphisms (data not shown).
In a similar way, mutations within the DNA binding domain,
especially in position 186, have been shown to disturb the
recognition of methylated Zta responsive elements within
promoter of lytic cycle genes [24]. Understanding differences
in the capability of natural variants concerning lytic cycle
induction could be most important, particularly since tumour
imaging following induction of the viral lytic cycle was also
suggested as a possible follow-up procedure in a preliminary
animal model [29]. Furthermore, this same animal model of
viral lytic cycle induction, combined with targeted radiation
therapy, proved to be an efﬁcient strategy to regress
EBV-related tumour growth in vivo [30].
In conclusion, we assessed for the ﬁrst time polymorphisms
in the BZLF1 gene in a series of paediatric patients in
Argentina. The evaluation of sequence variation in samples
from paediatric patients with IM at the time of diagnosis
allowed for the identiﬁcation of the original infecting variant in
contrast to co-infection with multiple variants often seen in
adult healthy carriers [31]. In addition to previously described
variants, we characterized three new phylogenetic groups
circulating in our region. Moreover, we suggest the association
of particular variants either with benign IM or with malignant
lymphomas. Taken together these observations could provide
some expansion of the existing knowledge about EBV
sequence variation and its association with malignancy and
the geographical distribution of EBV variants.
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